Retatrutide targets three receptors (GIP, GLP-1, and glucagon), potentially offering enhanced benefits
Pinch a fold of skin, insert the needle at a 90-degree angle, inject slowly over five seconds, hold for another five seconds, then withdraw without rubbing the site
It summarizes clinical trial results with new evidence on adherence, demographics and emerging indications and explains what it all means for patients and providers
Other concerning risks include intestinal blockages, pancreatitis, and rare but severe gallbladder complications such as cholecystitis (inflammation)
Key Takeaways The most common side effects are digestive issues like nausea, diarrhoea, vomiting, and constipation, similar to other GLP-1 medications Some participants experienced mild increases in heart rate at higher doses, but this decreased over time Side effects are typically worse when starting treatment or increasing doses, then improve as your body adjusts Long-term side effects are unknown as trials have only lasted up to one year so far Retatrutide is still in clinical trials and not available for prescription yet By entering I agree to the Terms and Conditions